Stockwatch: Big pharma looks on while Amgen splurges
This article was originally published in Scrip
It’s been a number of years since the pharmaceutical sector was held in the same esteem by investors for industries that are defensive and counter-cyclical; sectors whose sales and earnings growth continue even in a recession and, like tobacco and gambling, may increase in spite of it. The pharmaceutical industry used to have no natural predators, except itself and time.
You may also be interested in...
Biogen’s poor third-quarter results cannot be blamed solely on the pandemic. Pipeline attrition and underperformance in most franchises pushes all the risk onto a dubious throw of the regulatory dice.
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.